Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-PET for preoperative planning in melanoma surgery
NCT06560905Phase 2Recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in Malignant Melanoma (MM), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: PSMA PET-CT detection of melanoma metastases at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06560905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560905.